Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 8—August 2005


Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†Comments to Author , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Table A5

Relative risk (RR) and 95% confidence interval (95% CI) for influenza infection and protective efficacy of individual trials with estimate of preexposure (seasonal) prophylaxis

Trial Drug RR (95% CI) Protective efficacy (%) p value for heterogeneity
Hayden et al. (11) Oseltamivir 0.26 (0.13–0.50) 74
Monto et al. (15) Zanamivir 0.32 (0.17–0.63) 68
Overall 0.29 (0.20–0.43) 71 0.643

Main Article